Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $71.37, for a total transaction of $892,125.00. Following the completion of the sale, the chief financial officer owned 97,994 shares of the company's stock, valued at $6,993,831.78. This represents a 11.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Spyre Therapeutics Trading Down 6.8%
Shares of NASDAQ SYRE opened at $69.42 on Friday. The firm has a 50 day moving average of $51.75 and a 200 day moving average of $37.36. The firm has a market capitalization of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12. Spyre Therapeutics, Inc. has a 12-month low of $12.28 and a 12-month high of $76.00.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Thursday, February 19th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Sell-side analysts predict that Spyre Therapeutics, Inc. will post -2.8 EPS for the current year.
Institutional Investors Weigh In On Spyre Therapeutics
Several large investors have recently modified their holdings of SYRE. Optimize Financial Inc lifted its position in shares of Spyre Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company's stock valued at $830,000 after buying an additional 364 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Spyre Therapeutics by 0.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company's stock valued at $1,788,000 after purchasing an additional 522 shares during the last quarter. Summit Securities Group LLC purchased a new position in shares of Spyre Therapeutics in the 1st quarter valued at approximately $28,000. California State Teachers Retirement System raised its position in shares of Spyre Therapeutics by 1.8% in the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company's stock valued at $497,000 after purchasing an additional 603 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Spyre Therapeutics by 4.5% during the 4th quarter. AQR Capital Management LLC now owns 17,820 shares of the company's stock worth $584,000 after buying an additional 773 shares during the last quarter. Institutional investors own 80.39% of the company's stock.
Key Stories Impacting Spyre Therapeutics
Here are the key news stories impacting Spyre Therapeutics this week:
- Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
- Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
- Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (≈$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
- Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
- Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows
Analysts Set New Price Targets
Several equities analysts have weighed in on SYRE shares. Stifel Nicolaus lifted their price target on shares of Spyre Therapeutics from $70.00 to $92.00 and gave the company a "buy" rating in a report on Wednesday, March 18th. BTIG Research boosted their price target on shares of Spyre Therapeutics from $70.00 to $98.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. JonesTrading boosted their price target on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, April 17th. Leerink Partners boosted their price objective on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the company an "outperform" rating in a research report on Monday, April 13th. Finally, Raymond James Financial began coverage on shares of Spyre Therapeutics in a report on Monday, April 13th. They issued a "strong-buy" rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $85.08.
View Our Latest Analysis on SYRE
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
